Picture of the awards given at the AMILO conference

Happy anniversary AMILO!

MPELeave a comment

One of the MPE Spanish members, the Spanish Amyloidosis Association (AMILO), last month celebrated its fifth anniversary by recognising the support and help other organisations have given them during these five years. MPE is pleased and proud to receive this recognition from AMILO at such an important event for our member. Along with MPE, other important national and international organisations were awarded, like the Amyloidosis Alliance and the Spanish Society of Hematology, represented by its…

T2EVOLVE and QUALITOP launch European patient survey on CAR-T treatment

CAR-T, MyelomaLeave a comment

THE IMI T2EVOLVE Project and the Horizon 2020 QUALITOP Project have launched a European patient survey on CAR-T treatment. The survey aims to inform on patient and carer experiences and challenges of receiving CAR-T and to identify information needs and gaps across Europe. The results of the survey will be used for research purposes and published anonymously on project partner websites as well as in academic journals.   The T2EVOLVE-QUALITOP European patient survey on CAR-T…

Talquetamab generates high response rate in patients with hard-to-treat myeloma

Conferences, Myeloma, UncategorizedLeave a comment

NEW ORLEANS. New research being presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition focuses on talquetamab in patients with Relapsed/Refractory myeloma. In an early-phase trial, nearly three-quarters of patients who received talquetamab, a first-in-class experimental immunotherapy for myeloma, saw a significant reduction in cancer burden within a few months. The study participants had all been previously treated with at least three different therapies without achieving lasting remission, suggesting talquetamab could offer new…

Horizon Europe research project looks to improve the affordability and sustainability of innovative health technologies

Access, MPE, NewsLeave a comment

  Starting in December 2022, the HORIZON-funded project ASCERTAIN (Affordability and Sustainability improvements through new pricing, Cost- Effectiveness and Reimbursement models to Appraise innovative health technologies) will address the need of patients, physicians, payers, regulators, and manufacturers to improve the affordability and accessibility to innovative health technologies (including pharmaceuticals) in Europe. Affording newly approved innovative health technologies (IHTs) is challenging in many health systems.

Join MPE’s webinar on Access Barriers to Clinical Trials in CEE Countries

Access, MPE, NewsLeave a comment

Myeloma Patient Europe (MPE) has been aware of the lack of clinical trials opening in many Central and Eastern European (CEE) countries, as well as inequalities in access with CEE countries for participating in ongoing trials. To gather data on, and further understand the access situation, MPE conducted research on barriers and facilitators to clinical trials, with a specific focus on CEE countries. The research was completed under the guidance of MPE members from across the region through its CEE…

The European Medicines Agency (EMA) approves Melflufen (Pepaxti®) for the treatment of refractory myeloma

Access, MyelomaLeave a comment

  The European Commission has approved marketing authorisation (e.g. a license) for melphalan flufenamide (also called melflufen), a drug marketed in Europe by Oncopeptides with the name of Pepaxti®. This follows the previous positive recommendation from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP).